Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115173 | 0.87 | MEN1 (0.80) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL4124267 | 0.86 | LMNA (0.57) | MEN1KMT2ATDP1CRHBPCRHR2 | |
| SCHEMBL4118347 | 0.85 | LMNA (0.56) | MEN1KMT2ATDP1MAPTLMNA | |
| SCHEMBL4114160 | 0.83 | ALDH1A1 (0.59) | MEN1KMT2ATDP1CRHBPCRHR2 | |
| SCHEMBL4119968 | 0.83 | ALDH1A1 (0.61) | MEN1KMT2ATDP1CRHBPCRHR2 | |
| SCHEMBL4125608 | 0.76 | MEN1 (0.61) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL4120327 | 0.76 | LMNA (0.65) | MEN1KMT2ATDP1MAPTLMNA | |
| SCHEMBL4114264 | 0.75 | LMNA (0.79) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL4107138 | 0.75 | CNR1 (0.55) | MEN1KMT2ATDP1MAPTLMNA | |
| SCHEMBL4115503 | 0.73 | KMT2A (0.54) | MEN1KMT2ATDP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | MEN1 4167/4885KMT2A 2720/4885TDP1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.